Connect your AI

Anika Therapeutics ANIK Price / book

Price / book at other companies

VericelVCEL

4.6×-3.0×

Zimmer Biomet HoldingsZBH

1.4×-0.4×

Pacira BioSciences, Inc.PCRX

1.4×0.0×

BioventusBVS

3.3×-0.8×

Xtant Medical HoldingsXTNT

1.6×+0.1×

Globus MedicalGMED

2.5×0.0×

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

market cap/total stockholders equity=1.5×

Based on the most recent quarter.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's price / book?: Anika Therapeutics (ANIK) reported price / book of 1.5× in Q1 2026.
How has Anika Therapeutics's price / book changed year-over-year?: Anika Therapeutics's price / book increased by 1.1% year-over-year, from 1.4× to 1.5×.
What is the long-term trend for Anika Therapeutics's price / book?: Over 5 years (2020 to 2025), Anika Therapeutics's price / book has grown at a -16.6% compound annual growth rate (CAGR), from 2.4× to 1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.